FDA Drug recall D-1052-2016
Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-count bottles and b) 5000-count bottles, Rx only, Manufactured…
- FDA Drug
- Class III
- terminated
- Published 2016-07-06
On 2016-07-06 the FDA classified a Class III recall of Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-count bottles and b) 5000-count bottles, Rx only, Manufactured… by Lupin Pharmaceuticals, citing CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1052-2016 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2016-04-04 |
| Published | 2016-07-06 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Lupin Pharmaceuticals |
| Distribution | US |
Product
Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-count bottles and b) 5000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775 India, a) NDC 68180-519-01, b) 68180-519-30
Reason
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
Identifiers
| ndc | 68180-518-02 |
|---|---|
| ndc | 68180-518-01 |
| ndc | 68180-518-30 |
| ndc | 68180-519-30 |
| ndc | 68180-519-01 |
| ndc | 68180-519-02 |
| ndc | 68180-520-02 |
| ndc | 68180-520-30 |
| ndc | 68180-520-01 |
| code_info | Lot #: a) H303459, b) H303460, Exp 09/2016 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1052-2016%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.